Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses

Stock News

06/22

An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.

According to the prospectus, Suzhou Zelgen Biopharmaceutical Co., Ltd. (SSE: 688266) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1117535956"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117535956\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117535956?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 11:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117535956","market":"us","top_or_hot":-1,"title":"Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses","media":"Stock News","content":"<p>An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceutical Co., Ltd.</b> (<b>SSE: 688266</b>) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-22 11:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceutical Co., Ltd.</b> (<b>SSE: 688266</b>) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1117535956","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117535956","pubTimestamp":1782097579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药-U","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard","BK0239":"医药制造","BK1191":"制药","01477":"欧康维视生物-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"泽璟生物制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1,"VXUS":1,"IPOS":1,"01477":1},"content_text":"An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.According to the prospectus, Suzhou Zelgen Biopharmaceutical Co., Ltd. (SSE: 688266) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}